

Jrg H W Distler

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1153202/jorg-h-w-distler-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

208
papers

18,592
citations

65
h-index

134
g-index

225
ext. papers

23,688
ext. citations

5.9
avg, IF

6.9
L-index

#	Paper	IF	Citations
208	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
207	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , 2021 , 11, 1	4.9	2785
206	Activation of canonical Wnt signalling is required for TGF- β -mediated fibrosis. <i>Nature Communications</i> , 2012 , 3, 735	17.4	501
205	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1327-1339	2.4	497
204	MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1733-43		409
203	The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 2892-7	11.5	336
202	Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 311-22		317
201	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1188-94	2.4	267
200	Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. <i>Circulation Research</i> , 2004 , 95, 109-16	15.7	248
199	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1897-1905	2.4	230
198	Evidence of innate lymphoid cell redundancy in humans. <i>Nature Immunology</i> , 2016 , 17, 1291-1299	19.1	196
197	Orphan nuclear receptor NR4A1 regulates transforming growth factor- β -signaling and fibrosis. <i>Nature Medicine</i> , 2015 , 21, 150-8	50.5	195
196	Platelet-derived serotonin links vascular disease and tissue fibrosis. <i>Journal of Experimental Medicine</i> , 2011 , 208, 961-72	16.6	190
195	Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3337-48		179
194	Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. <i>PLoS Genetics</i> , 2011 , 7, e1002091	6	176
193	Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. <i>FASEB Journal</i> , 2008 , 22, 2214-22	0.9	169
192	Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 219-24		162

191	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. <i>Nature Communications</i> , 2017 , 8, 1130	17.4	155
190	ImmunoChip analysis identifies multiple susceptibility loci for systemic sclerosis. <i>American Journal of Human Genetics</i> , 2014 , 94, 47-61	11	151
189	Ecaterin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 761-7	2.4	147
188	Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4203-15		139
187	The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1232-9	2.4	136
186	Shared and distinct mechanisms of fibrosis. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 705-730	8.1	134
185	Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2755-64		134
184	Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1468-76		133
183	Microparticles as mediators of cellular cross-talk in inflammatory disease. <i>Autoimmunity</i> , 2006 , 39, 683-90		131
182	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 883-90	2.4	120
181	Targeting TGF- β signaling for the treatment of fibrosis. <i>Matrix Biology</i> , 2018 , 68-69, 8-27	11.4	116
180	Animal models of systemic sclerosis: prospects and limitations. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2831-44		113
179	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2724-33		110
178	Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1475-84		103
177	Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 856-64		103
176	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016 , 11, e0163894	3.7	99
175	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1304-10	2.4	97
174	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1941-1948	2.4	96

173	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 979-987	2.4	95
172	Sirt1 regulates canonical TGF- β signalling to control fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 226-33	2.4	94
171	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1255-8	2.4	92
170	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1396-404		92
169	The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1129-36		91
168	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	90
167	JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3006-15		89
166	Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2553-64		88
165	Vitamin D receptor regulates TGF- β signalling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e20	2.4	87
164	Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1519-29		87
163	Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. <i>Circulation</i> , 2009 , 120, 2367-76	16.7	85
162	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 575-85	6.3	83
161	The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 280-90		83
160	Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 10-23		83
159	Inhibition of glycogen synthase kinase 3 induces dermal fibrosis by activation of the canonical Wnt pathway. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2191-8	2.4	82
158	Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 897-904	6.9	81
157	Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. <i>Arthritis and Rheumatism</i> , 2006 , 54, 214-25		81
156	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1382-7	2.4	80

155	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. <i>Human Molecular Genetics</i> , 2012 , 21, 2825-35	5.6	79
154	Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 614-20	2.4	78
153	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF β signalling. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1408-16	2.4	78
152	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2845-53		77
151	Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2009 , 11, 2205-7		73
150	Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1203-10	2.4	71
149	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1207-1218	2.4	71
148	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. <i>Human Molecular Genetics</i> , 2012 , 21, 926-33	5.6	70
147	Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1545-51	2.4	69
146	Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3564-74		69
145	PU.1 controls fibroblast polarization and tissue fibrosis. <i>Nature</i> , 2019 , 566, 344-349	50.4	67
144	Inhibition of activator protein 1 signaling abrogates transforming growth factor β mediated activation of fibroblasts and prevents experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1642-52		65
143	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1019-26	2.4	65
142	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 800-9		63
141	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 785-9	2.4	63
140	The tyrosine phosphatase SHP2 controls TGF β induced STAT3 signaling to regulate fibroblast activation and fibrosis. <i>Nature Communications</i> , 2018 , 9, 3259	17.4	60
139	Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1880-7	2.4	60
138	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 623-6	2.4	59

137	Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1575-80	2.4	57
136	Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis. <i>Journal of Immunology</i> , 2018 , 200, 1249-1254	5.3	54
135	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	52
134	The role of membrane lipids in the induction of macrophage apoptosis by microparticles. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007 , 12, 363-74	5.4	52
133	Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3467-76		51
132	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1621-5	2.4	49
131	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2012 , 120, 2909-17	2.2	49
130	New insight on the Xq28 association with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 2032-8	2.4	48
129	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	48
128	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019 , 10, 4955	17.4	46
127	Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 257-267	9.5	46
126	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 737-45	2.4	46
125	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1285-92	2.4	45
124	Autophagy: a key pathway of TNF-induced inflammatory bone loss. <i>Autophagy</i> , 2013 , 9, 1253-5	10.2	45
123	The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1320-6	2.4	45
122	Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1485-1491	2.4	45
121	The Fra-2 transgenic mouse model of systemic sclerosis. <i>Vascular Pharmacology</i> , 2013 , 58, 194-201	5.9	44
120	Innovative antifibrotic therapies in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 274-80	5.3	43

119	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 137-149	9.5	42
118	Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1133-1141	2.4	40
117	Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*. <i>Experimental Dermatology</i> , 2005 , 14, 315-20	4	40
116	Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?. <i>Experimental Dermatology</i> , 2013 , 22, 710-3	4	39
115	Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 756-62	5.6	38
114	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 96-106	35.1	38
113	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 303-10	2.4	37
112	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018 , 57, 370-381	3.9	36
111	Canonical Wnt signaling in systemic sclerosis. <i>Laboratory Investigation</i> , 2016 , 96, 151-5	5.9	36
110	Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2538-42		36
109	Emerging strategies for treatment of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 186-193	2.3	36
108	Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2338-44	9.5	35
107	S100A4 amplifies TGF- β -induced fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1748-55	2.4	34
106	Induction of apoptosis in circulating angiogenic cells by microparticles. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2067-77		34
105	The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1081-7	2.4	33
104	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 150-158	2.4	32
103	The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. <i>PLoS ONE</i> , 2013 , 8, e54419	3.7	32
102	Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. <i>Current Rheumatology Reports</i> , 2011 , 13, 21-7	4.9	32

101	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 563-570	2.4	31
100	Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3168-79		31
99	Inhibition of casein kinase II reduces TGF β -induced fibroblast activation and ameliorates experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 936-43	2.4	30
98	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1089-98	2.4	30
97	Cardiomyopathy in murine models of systemic sclerosis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 508-16	9.5	29
96	Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1521-6	2.4	29
95	Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1264-8	2.4	29
94	The transcription factor GLI2 as a downstream mediator of transforming growth factor- β -induced fibroblast activation in SSc. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 756-764	2.4	28
93	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1467-1475	2.4	28
92	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 744-751	2.4	27
91	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 459	2.4	27
90	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1895-9	2.4	27
89	Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. <i>Experimental Dermatology</i> , 2017 , 26, 73-81	4	26
88	Influence of the IL6 gene in susceptibility to systemic sclerosis. <i>Journal of Rheumatology</i> , 2012 , 39, 2294-302	4.1	26
87	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2019 , 38, 2673-2681	3.9	25
86	Inhibition of sumoylation prevents experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1904-8	2.4	25
85	Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. <i>American Journal of Pathology</i> , 2012 , 181, 1672-80	5.8	25
84	Activating transcription factor 3 regulates canonical TGF β signalling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 586-92	2.4	24

83	Epigenetic factors as drivers of fibrosis in systemic sclerosis. <i>Epigenomics</i> , 2017 , 9, 463-477	4.4	24
82	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1317-24	2.4	24
81	Tribbles homologue 3 stimulates canonical TGF- β signalling to regulate fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 609-16	2.4	24
80	TGF- β -induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2347-2363	15.9	24
79	Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. <i>Archives of Dermatological Research</i> , 2013 , 305, 1-8	3.3	23
78	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 244-251	2.4	22
77	Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 624-7	2.4	22
76	Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 2051-4	2.4	22
75	Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. <i>Molecular Pharmacology</i> , 2004 , 65, 389-99	4.3	21
74	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 212-218	2.3	19
73	Activation of pregnane X receptor inhibits experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 621-5	2.4	19
72	Tie2 as a novel key factor of microangiopathy in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 105	5.7	19
71	Morphogen pathways in systemic sclerosis. <i>Current Rheumatology Reports</i> , 2013 , 15, 299	4.9	19
70	Long noncoding RNA H19X is a key mediator of TGF- β -driven fibrosis. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4888-4905	15.9	19
69	Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 2039-46	2.4	17
68	Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1197-202	2.4	17
67	Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1513-22		16
66	Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2037-2044	2.4	16

65	Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 773-778	2.4	15
64	From pathogenesis to therapy--Perspective on treatment strategies in fibrotic diseases. <i>Pharmacological Research</i> , 2015 , 100, 93-100	10.2	15
63	Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. <i>Journal of Controlled Release</i> , 2019 , 310, 198-208	11.7	15
62	Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1686-1692	2.4	15
61	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology</i> , 2015 , 54, 2273-82	3.9	14
60	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	14
59	Updates on animal models of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016 , 1, 266-276	2.3	14
58	Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 439-447	4.3	13
57	Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3663-75		13
56	Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 836	2.4	13
55	Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	13
54	NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 2035-2047	6.3	13
53	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S75-9	2.2	13
52	Acyltransferase skinny hedgehog regulates TGF β -dependent fibroblast activation in SSc. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1269-1273	2.4	12
51	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. <i>British Journal of Pharmacology</i> , 2020 , 177, 4296-4309	8.6	12
50	Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 455-62	5.1	12
49	The nuclear receptor constitutive androstane receptor/NR113 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 3140-50	9.5	12
48	Innate lymphoid cells and fibrotic regulation. <i>Immunology Letters</i> , 2018 , 195, 38-44	4.1	11

47	Tocilizumab for systemic sclerosis: implications for future trials. <i>Lancet, The</i> , 2016 , 387, 2580-2581	4.0	11
46	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 626-628	2.4	10
45	Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 936-47	6.3	10
44	Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1385-1395	9.5	9
43	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020 , 59, 1684-1694	3.9	9
42	⁶⁸ Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e185-e194	14.2	9
41	Autoantibodies Recognizing Secondary Necrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018 , 9, 989	8.4	8
40	Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 2068-2080	9.5	8
39	Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 4185-91	5.6	8
38	Cellular and molecular mechanisms in fibrosis. <i>Experimental Dermatology</i> , 2021 , 30, 121-131	4	8
37	TGFβ promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. <i>Nature Communications</i> , 2021 , 12, 4404	17.4	8
36	Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. <i>PLoS ONE</i> , 2020 , 15, e0229445	3.7	7
35	Novel treatment approaches to fibrosis in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2008 , 34, 145-59; vii	2.4	7
34	Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial. <i>Arthritis Research and Therapy</i> , 2021 , 23, 112	5.7	7
33	Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 920-929	2.4	7
32	PGC-1β regulates autophagy to promote fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1227-1233	2.4	6
31	Therapeutic molecular targets of SSc-ILD.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 17-30	2.3	6
30	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2021 , 137, 2403-2416	2.2	5

29	Comment on: Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria by Greco. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e85	2.4	5
28	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	5
27	Response to: Correspondence on Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis by Jeny. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
26	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S31-5	2.2	4
25	microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 523, 1001-1006	3.4	3
24	The scientific basis for novel treatments of systemic sclerosis. <i>F1000 Medicine Reports</i> , 2009 , 1,		3
23	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 3939-3951	3.9	3
22	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e175-e184	14.2	3
21	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1681-1685	2.4	3
20	The α 7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2371-2379	4.3	2
19	Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 160-4		2
18	Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 681061	5.7	2
17	Mouse Models of Skin Fibrosis. <i>Methods in Molecular Biology</i> , 2021 , 2299, 371-383	1.4	2
16	Platelet phagocytosis via PSGL1 and accumulation of microparticles in systemic sclerosis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	2
15	LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis.. <i>Clinical and Translational Medicine</i> , 2022 , 12, e711	5.7	1
14	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicines</i> , 2021 , 9,	4.8	1
13	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. <i>Arthritis Research and Therapy</i> , 2021 , 23, 204	5.7	1
12	Reply. <i>Arthritis and Rheumatology</i> , 2021 , 73, 179-180	9.5	1

11	Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	1
10	The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221074457	3.8	1
9	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 134-141	2.2	1
8	Response to: An search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes? Pby Manetti and Matucci-Cerinic. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e150	2.4	0
7	Patient Perception of Digital Symptom Assessment Technologies in Rheumatology: Results From a Multicentre Study.. <i>Frontiers in Public Health</i> , 2022 , 10, 844669	6	0
6	A3.19 miR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A49.2-A49	2.4	
5	A8.3 Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A58.1-A58	2.4	
4	Anti-Fibrotic Effect of Ajulemic Acid in Bleomycin-Induced Lung Fibrosis. <i>FASEB Journal</i> , 2015 , 29, LB7440.9		
3	Overview of Animal Models 2017 , 281-293		
2	Quantification of ⁶⁸ Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease [Authors' reply]. <i>Lancet Rheumatology</i> , 2021 , 3, e475-e477	14.2	
1	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 134-141	2.2	